Get the Stockscreener App
138.01
1.58%
2.14
Pre-market:
138.46
0.45
+0.33%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $138.01, with a volume of 8.19M.
It is up +1.58% in the last 24 hours and up +7.88% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$135.87
Open:
$136.4
24h Volume:
8.19M
Relative Volume:
1.53
Market Cap:
$239.35B
Revenue:
$41.95B
Net Income/Loss:
$13.40B
P/E Ratio:
18.04
EPS:
7.65
Net Cash Flow:
$6.35B
1W Performance:
+2.29%
1M Performance:
+7.88%
6M Performance:
+21.84%
1Y Performance:
+16.33%
1-Day Range:
$134.75
$138.37
1-Week Range:
$134.27
$138.37
52-Week Range:
$99.71
$138.37
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
138.01 | 239.35B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
103.79 | 153.17B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
386.19 | 147.36B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.02 | 118.00B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.62 | 42.24B | 5.72B | 4.17B | 490.10M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Is Abbott Laboratories Stock Outperforming the Dow? - TradingView
Anchor Capital Advisors LLC Sells 2,673 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Mutual of America Capital Management LLC Has $23.47 Million Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Flputnam Investment Management Co. Acquires 5,168 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Sold by Los Angeles Capital Management LLC - MarketBeat
15,365 Shares in Abbott Laboratories (NYSE:ABT) Bought by DMKC Advisory Services LLC - MarketBeat
Bank of New York Mellon Corp Buys 30,097 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Pine Valley Investments Ltd Liability Co Grows Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
FourThought Financial Partners LLC Boosts Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
IFP Advisors Inc Purchases 2,860 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
South Dakota Investment Council Has $444,000 Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Richard Bernstein Advisors LLC Has $6.71 Million Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Vaughan David Investments LLC IL Grows Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories stock rises Friday, still underperforms market - MarketWatch
Abbott stock hits 52-week high at $137.12 amid robust growth - Investing.com
Abbott Laboratories (NYSE:ABT) Sets New 52-Week HighTime to Buy? - MarketBeat
Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.
What Does the Market Think About Abbott Laboratories? - Benzinga India
QRG Capital Management Inc. Grows Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Investors Shouldn't Be Too Comfortable With Abbott Laboratories' (NYSE:ABT) Earnings - Simply Wall St
dPCR and qPCR Market to Witness Remarkable Growth with | Abbott Laboratories (US), Qiagen N.V. (Germany) - openPR
Litigators of the Week: In Class Action Trial Over PediaSure Label Claims, a Complete Defense Verdict for Abbott - Law.com
With 79% ownership of the shares, Abbott Laboratories (NYSE:ABT) is heavily dominated by institutional owners - Yahoo Finance
Abbott Laboratories closes flat after six sessions of gains - MSN
Abbott Laboratories closes flat after six sessions of gains (ABT:NYSE) - Seeking Alpha
Abbott (ABT) Stock Moves -0.07%: What You Should Know - Yahoo Finance
Abbott Beats Ill. Customers' Similac Metals Suit - Law360
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Mn Services Vermogensbeheer B.V. Has $77.57 Million Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Concussion Market Projected To Witness Substantial Growth, 2025-2032: Abbott Laboratories, BrainScope Company - EIN News
Catheter Market Global Report and Company Analysis - GlobeNewswire
Catheter Market Global Report and Company Analysis 2025-2033 Featuring Abbott Laboratories, BD and Co, Boston Scientific, Teleflex, Medtronic, Johnson & Johnson, Edwards Lifesciences, Stryker - Yahoo Finance
Tradewinds Capital Management LLC Has $989,000 Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Sigma Planning Corp Sells 2,763 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Cancer Cell Market Is Booming Worldwide 2025-2032 | Abbott Laboratories, Novartis International AG, Arcellx - openPR
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
Greystone Financial Group LLC Buys 4,549 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Urinalysis Market Future Business Opportunities 2025-2032 | Arkray Inc., Abbott Laboratories, Eiken Chemical Co. Ltd. - openPR
Biochips Market Growth | Trends, Size & Forecast 2024-2031 | Abbott Laboratories, PerkinElmer Inc., Illumina, Inc. - openPR
Abbott Laboratories Soars: Profit Doubling Sparks Market Interest - Jomfruland.net
Abbott Laboratories Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Abbott Laboratories price soarsForecast today24-02-2025 - Economies.com
Abbott Laboratories (NYSE:ABT) Plans $0.59 Quarterly Dividend - MarketBeat
Clinical Laboratory Tests Market Set to Witness Significant Growth by 2025-2032: Sonic Healthcare Limited., - EIN News
ING Groep NV Has $40 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Declares 405th Consecutive Quarterly Dividend of US$0.59 Per Share - Simply Wall St
Abbott Laboratories' (NYSE:ABT) five-year earnings growth trails the 14% YoY shareholder returns - Yahoo Finance
Abbott India Namita ShahAssociate DirectorNew Product Introduction and Therapy Area Strategy to... - Medical Dialogues
Widespread Damage Warrants Caution; Abbott Labs, Tradeweb, ICE In Focus - Investor's Business Daily
Abbott (ABT) Gains As Market Dips: What You Should Know - Yahoo Finance
Abbott Laboratories stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.97%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):